The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape, which has historically been dominated by chemotherapy regimens. However, only about 20% of patients will benefit from immune checkpoint inhibitor therapy, after which effective alternative therapies are severely limited. The FDA’s 2019 approval of Balversa (Johnson & Johnson) has provided an additional treatment option for the 15-20% of patients with susceptible FGFR alterations. However, given the dismal overall survival for patients with distant metastases, a significant level of unmet need remains in the bladder cancer drug market.

Questions Answered

  •  How important are clinical drug attributes in medical oncologists’ prescribing decisions? What are the key influencers on treatment decisions and the hidden opportunities that drug developers could leverage?
  • How do key current therapies, such as Tecentriq (Roche) and Keytruda (Merck & Co.), perform on key clinical drug attributes for this patient population? Are medical oncologists satisfied with current therapies?
  • What are the greatest unmet needs and most attractive opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across key drug attributes and price when considering a hypothetical target product profile?

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in December 2019.

Key companies:  Merck & Co., Roche / Genentech, Bristol-Myers Squibb, Merck KGaA / Pfizer, AstraZeneca, Johnson & Johnson.

Key drugs: Keytruda, Tecentriq, Opdivo, Bavencio, Imfinzi, Balversa.

Table of contents

  • Detailed, Expanded Analysis (US/EU5)
    • Executive Summary
      • Unmet Need - Bladder Cancer - Executive Summary - March 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Unresectable Locally Advanced or Metastatic Bladder Cancer
      • Key Findings: Unmet Need in Unresectable Locally Advanced or Metastatic Bladder Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Unresectable Locally Advanced or Metastatic Bladder Cancer Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent with Improved Survival Benefit
        • Opportunity: A New Therapy with Delayed Progression-Free Survival
        • Opportunity: A Novel Therapy That Improves Tumor Response
        • Opportunity: A New Agent with an Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • First-Line Unresectable Locally Advanced or Metastatic Bladder Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Market Scenario
    • Appendix
      • Bibliography

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, , is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at University of Science & Technology, Hisar, India.

Related Reports

Bladder Cancer | Landscape & Forecast | Disease Landscape & Forecast

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically...

View Details

Bladder Cancer | Current Treatment | Detailed, Expanded Analysis: Physician Insights (US)

The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s...

View Details

Bladder Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Bladder Cancer | Geographic Focus: China | China In-Depth

Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period...

View Details